Insider Selling: Edwards Lifesciences Corp. VP Sells 4,850 Shares of Stock (EW)
Edwards Lifesciences Corp. (NYSE:EW) VP Huimin Wang sold 4,850 shares of Edwards Lifesciences Corp. stock in a transaction dated Friday, October 4th. The shares were sold at an average price of $72.19, for a total transaction of $350,121.50. Following the transaction, the vice president now directly owns 31,337 shares in the company, valued at approximately $2,262,218. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of analysts have recently weighed in on EW shares. Analysts at RBC Capital reiterated a “hold” rating on shares of Edwards Lifesciences Corp. in a research note to investors on Thursday, October 3rd. They now have a $75.00 price target on the stock. Separately, analysts at Stifel Nicolaus raised their price target on shares of Edwards Lifesciences Corp. from $81.00 to $82.00 in a research note to investors on Thursday, October 3rd. They now have a “buy” rating on the stock. Finally, analysts at Canaccord Genuity reiterated a “buy” rating on shares of Edwards Lifesciences Corp. in a research note to investors on Tuesday, September 10th. They now have a $90.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and thirteen have issued a buy rating to the company’s stock. Edwards Lifesciences Corp. currently has an average rating of “Buy” and a consensus target price of $80.75.
Shares of Edwards Lifesciences Corp. (NYSE:EW) traded down 0.26% during mid-day trading on Tuesday, hitting $72.39. 1,241,054 shares of the company’s stock traded hands. Edwards Lifesciences Corp. has a 52 week low of $62.34 and a 52 week high of $94.98. The stock’s 50-day moving average is $71.06 and its 200-day moving average is $71.06. The company has a market cap of $8.127 billion and a price-to-earnings ratio of 21.22.
Edwards Lifesciences Corp. (NYSE:EW) last announced its earnings results on Thursday, July 25th. The company reported $0.82 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.76 by $0.06. The company had revenue of $517.20 million for the quarter, compared to the consensus estimate of $514.59 million. During the same quarter last year, the company posted $0.57 earnings per share. Edwards Lifesciences Corp.’s revenue was up 7.3% compared to the same quarter last year. On average, analysts predict that Edwards Lifesciences Corp. will post $3.07 earnings per share for the current fiscal year.
Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.